Ftse Mib
33.736,40
0,00%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.482,14
0,61%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ OptiNose Inc (OPTN) OptiNose Inc (OPTN) Notizie

OptiNose Inc

OPTN
0,876
-0,0322 (-3,55%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202413:00GLOBEOptinose Provides Corporate Update on XHANCE Launch and..
04/4/202422:01GLOBEOptinose to Present at the Needham Virtual Healthcare..
15/3/202420:34GLOBEXHANCE Approved by FDA as First and Only Medication..
08/3/202422:10EDGAR2Form 8-K - Current report
07/3/202422:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202413:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202413:00GLOBEOptinose Reports Fourth Quarter and Full Year 2023 Financial..
07/3/202413:00EDGAR2Form 8-K - Current report
29/2/202422:40GLOBEOptinose Announces Reporting Date for Fourth Quarter 2023..
29/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202413:08EDGAR2Form 8-K - Current report
22/2/202422:28EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202402:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202423:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202420:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202418:00GLOBEOptinose Announces the Publication of ReOpen Phase 3..
21/12/202322:11EDGAR2Form 8-K - Current report
20/12/202318:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202318:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202314:48DJNOptinose Shares Slide Premarket as FDA Extends Xhance Review
06/12/202313:02EDGAR2Form 8-K - Current report
06/12/202313:00GLOBEOptinose Announces 3-Month Extension of FDA Review Period..
22/11/202315:00GLOBEOptinose to Present at the 35th Annual Piper Sandler..
09/11/202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:02EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEOptinose Reports Third Quarter 2023 Financial Results and..
27/10/202314:00GLOBEOptinose Announces Reporting Date for Third Quarter 2023..
22/9/202315:01GLOBEOptinose to Present at the 2023 Cantor Global Healthcare..
20/9/202301:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202301:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
10/8/202322:05EDGAR2Form S-3 - Registration statement under Securities Act of..
10/8/202313:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:02EDGAR2Form 8-K - Current report
10/8/202313:00GLOBEOptinose Reports Second Quarter 2023 Financial Results and..
27/7/202313:27EDGAR2Form 8-K - Current report
27/7/202313:00GLOBEOptinose Announces Preliminary Second Quarter 2023 XHANCE..
16/6/202322:08GLOBEOptinose Announces Inducement Grant Under Nasdaq Listing..
02/6/202319:00GLOBEOptinose to Present at the Jefferies Healthcare Conference
11/5/202313:00GLOBEOptinose Reports First Quarter 2023 Financial Results and..
04/5/202313:00GLOBEOptinose Announces FDA Acceptance of Supplemental New Drug..
Apertura: 0,9191 Min: 0,8705 Max: 0,925
Chiusura: 0,9082

La tua Cronologia

NASDAQ
OPTN
OptiNose
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network